- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 17.06. | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| ZENAS BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 11.06. | Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit | 1 | GlobeNewswire (USA) | ||
| 03.06. | H.C. Wainwright bestätigt Kaufempfehlung für Zenas Biopharma nach Studienerfolg | 3 | Investing.com Deutsch | ||
| 03.06. | H.C. Wainwright reiterates Zenas Biopharma stock rating at buy | 1 | Investing.com | ||
| 03.06. | Zenas BioPharma reports positive phase 3 trial results for obexelimab | 2 | Investing.com | ||
| 03.06. | Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine | 2 | GlobeNewswire (USA) | ||
| 28.05. | Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD | 468 | GlobeNewswire (Europe) | - BLA submission based on positive results from Phase 3 INDIGO trial - WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas," "Zenas BioPharma" or the "Company") (Nasdaq:... ► Artikel lesen | |
| 19.05. | Zenas BioPharma präsentiert Studiendaten zu Obexelimab auf dem EULAR-Kongress | 1 | Investing.com Deutsch | ||
| 19.05. | Zenas BioPharma to present obexelimab trial data at EULAR congress | 3 | Investing.com | ||
| 19.05. | Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress | 290 | GlobeNewswire (Europe) | - Safety and efficacy results from the Phase 3 INDIGO trial to be presented by Emanuel Della Torre, M.D., Ph.D., on Thursday June 4, 2026, at 2:45 PM GMT - WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 18.05. | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 13.05. | Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor | 254 | GlobeNewswire (Europe) | - Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB021 in healthy volunteers and to establish proof-of-concept in patients with plaque psoriasis - -... ► Artikel lesen | |
| 13.05. | Zenas BioPharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | Zenas BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Zenas BioPharma GAAP EPS of -$1.46 beats by $0.22 | 2 | Seeking Alpha | ||
| 13.05. | Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update | 607 | GlobeNewswire (Europe) | - Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on the Phase 3 INDIGO IgG4-RD trial results - - Obexelimab... ► Artikel lesen | |
| 30.04. | Zenas BioPharma rises as CEO continues insider purchases | 1 | Seeking Alpha | ||
| 17.04. | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 4 | GlobeNewswire (USA) | ||
| 31.03. | Zenas BioPharma, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,146 | -2,94 % | BRANDMELDUNG bei Valneva: Warum Insider bereits massiv kaufen - So reagieren erfahrene Anleger jetzt | ||
| AMGEN | 318,50 | -1,94 % | After Antibiotic Approval, Spero Pivots to Immunology Aiming to Rival an Amgen Asset | ||
| REGENERON PHARMACEUTICALS | 590,00 | -0,57 % | Attovia files for IPO to take on Sanofi and Regeneron's Dupixent | ||
| VIVOSIM LABS | 0,580 | 0,00 % | VivoSim Labs, Inc.: VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027 | SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,170 | -2,09 % | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update
Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 52,12 | -0,42 % | BioMarin Pharmaceutical Inc.: U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO (vosoritide) for Children With Achondroplasia | Application based on long-term safety and efficacy data from three ongoing studies, including adult height and additional clinical outcomes beyond linear growth... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,000 | -0,40 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| ARROWHEAD PHARMACEUTICALS | 63,88 | +2,40 % | This Arrowhead Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday | ||
| TRAWS PHARMA | 0,670 | 0,00 % | Traws Pharma, Inc.: Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program | NEWTOWN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, Traws, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral... ► Artikel lesen | |
| VERASTEM | 5,090 | +0,47 % | RBC Capital Reaffirms Outperform Rating For Verastem (VSTM) | ||
| UNIQURE | 34,900 | +1,45 % | uniQure - QURE: Ist das die nächste Kursrakete im Biotech-Sektor?! | Gentherapie-Spezialist! Spekulativer Biotech-Wert mit hoher Volatilität: uniQure-Aktie (QURE) - Fokus auf Studienergebnisse, Zulassungen und regulatorischen Entscheidungen! uniQure (QURE) - IL0011559904... ► Artikel lesen | |
| TRINITY BIOTECH | 0,345 | -6,91 % | Trinity Biotech plc: Trinity Biotech's Trinovium Secures Open Compute Project Membership, Advancing Hyperscale Market Access and Commercial Validation for AI Data Center Liquid Cooling | - Milestone an important step in launching Trinovium within the global AI data center ecosystem - Data center liquid cooling market projected to expand from $4 billion in 2026 to $27 billion by... ► Artikel lesen | |
| ZAI LAB LTD ADR | 17,100 | -6,04 % | Zai Lab Limited: Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas | Zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, showed a 53.7% confirmed intracranial objective response rate (iORR) for small cell lung cancer (SCLC) with brain metastases... ► Artikel lesen | |
| INSMED | 94,72 | +0,82 % | Insmed Announces Positive 12-Month Data From OLE Study Of Treprostinil Palmitil Inhalation Powder | WASHINGTON (dpa-AFX) - Thursday, Insmed Incorporated (INSM) announced positive 12-Month data from the ongoing open-label extension or OLE study, evaluating treprostinil palmitil inhalation powder... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 2,722 | +3,26 % | Voyager Therapeutics, Inc.: Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 | - Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging... ► Artikel lesen |
Das Unternehmen ZENAS BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 29,500 Euro und damit +4,42 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENAS BIOPHARMA INC finden Sie auf Wallstreet Online.